BTBP(SH:600161) Shang Hai Zheng Quan Bao·2025-11-24 18:19Core Viewpoint - The announcement details a non-compensatory transfer of shares from a subsidiary of the controlling shareholder to the parent company, which will not change the control structure of the company [2][3]. Group 1: Share Transfer Details - Beijing Tian Tan Biological Products Co., Ltd. (the "Company") announces that its controlling shareholder, China National Pharmaceutical Group Co., Ltd. ("China Bio"), will transfer 18,802,366 shares (0.95% of total shares) from its wholly-owned subsidiary, Beijing Biological Products Research Institute Co., Ltd. ("Beijing Institute"), to China Bio without compensation [2][4]. - After the transfer, China Bio will directly hold 921,302,854 shares, representing 46.59% of the total share capital, while Beijing Institute will no longer hold any shares [2][4]. - The total shares held by China Bio and its concerted parties will remain unchanged at 991,120,289 shares, accounting for 50.12% of the total share capital [2]. Group 2: Control and Regulatory Implications - This equity change will not result in a change of the controlling shareholder or the actual controller of the Company [3][5]. - The transfer does not trigger a mandatory tender offer and does not require the disclosure of an equity change report, acquisition report, or tender offer report [5]. - Subsequent to the transfer, the Company will need to complete share transfer registration and will fulfill its information disclosure obligations based on the progress of the matter [5].